论文部分内容阅读
目的:观察研究重组人白细胞介素-11治疗急性髓系白血病化疗后血小板减少的临床疗效。方法:我院在2012年6月-2014年6月间收治的40例急性髓系白血病患者,随机分为两组,每组各20例。对照组采用静脉滴注血小板治疗,观察组在化疗结束后,采用重组人白细胞介素-11治疗,比较两组患者的血小板计数与骨髓巨核细胞数以及血小板输注量。结果:观察组的血小板计数最低值高于对照组,血小板计数达到100×109/L的时间明显低于对照组,对比差异有统计学意义(P<0.05)。观察组血小板输注量明显低于对照组,骨髓巨核细胞数量高于对照组,对比差异有统计学意义(P<0.05)。两组患者的不良反应发生率均为15.0%,差异无统计学意义(P>0.05)。结论:重组人白细胞介素-11在急性髓系白血病化疗后血小板减少的治疗中有着较高的应用价值,有利于缩短血小板恢复时间,减轻不良反应,值得临床推广应用。
Objective: To observe the clinical efficacy of recombinant human interleukin-11 in the treatment of acute myeloid leukemia after thrombocytopenia. Methods: Forty patients with acute myeloid leukemia who were treated in our hospital from June 2012 to June 2014 were randomly divided into two groups, 20 cases in each group. The control group was treated with intravenous drip platelet. After the chemotherapy, the observation group was treated with recombinant human interleukin-11. The platelet counts, the number of megakaryocytes and the platelet transfusion volume in two groups were compared. Results: The lowest value of platelet count in observation group was higher than that in control group. The time of platelet count reaching 100 × 109 / L was obviously lower than that of control group (P <0.05). The amount of platelet transfusion in the observation group was significantly lower than that in the control group, and the number of bone marrow megakaryocytes was higher than that in the control group, with significant difference (P <0.05). Adverse reactions in both groups were 15.0%, with no significant difference (P> 0.05). Conclusion: Recombinant human interleukin-11 has a high value in the treatment of thrombocytopenia after acute myeloid leukemia chemotherapy, which will help shorten the recovery time of platelets and reduce adverse reactions, which is worthy of clinical application.